N-(9-antracenylmethyl)cinchonidinium bromide

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 金鸡纳生物碱
• 英文名称: N-(9-antracenylmethyl)cinchonidinium bromide
• 英文别名: (R)-[(2S,4S,5R)-1-(anthracen-9-ylmethyl)-5-ethenyl-1-azoniabicyclo[2.2.2]octan-2-yl]-quinolin-4-ylmethanol;bromide
• 化学式: Br*C₃₄H₃₃N₂O
• 分子量: 565.553
• InChiKey: SAWDNLRFSKEQGG-YFKOWXRZSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  4.19
• 重原子数：
  38
• 可旋转键数：
  5
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  辛可尼丁 、 9-溴甲基蒽 以 乙腈 为溶剂， 生成 N-(9-antracenylmethyl)cinchonidinium bromide
  参考文献：
  名称：

  Development of a Phase-Transfer-Catalyzed, [2,3]-Wittig Rearrangement

  摘要：

  An investigation into the use of phase-transfer catalysis for the [2,3]-sigmatropic rearrangement of allyloxy carbonyl compounds is described. Initial studies focused on identifying viable substrate classes that would undergo selective [2,3]-rearrangement under phase-transfer catalysis. Under certain conditions, the [2,3]-sigmatropic rearrangement of allyloxy carbonyl compounds takes place in the presence of a phase-transfer agent, providing a rare example of a phase-transfer-catalyzed unimolecular reaction. In the course of this investigation, it was found that catalysis is dependent on several variables including base concentration, catalyst structure, and substrate lipophilicity. Preliminary testing of chiral, nonracemic phase-transfer catalysts has shown promising levels of enantioselectivity for future development.

  DOI：

  10.1021/acs.joc.5b01759
• 作为试剂：
  描述：

  N-二苯亚甲基-甘氨酸叔丁酯 在 palladium on activated charcoal 氢氧化钾 、 sodium tetrahydroborate 、 N-(9-antracenylmethyl)cinchonidinium bromide 、 氢气 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 15.0h， 生成 鸟氨酸叔丁酯
  参考文献：
  名称：

  手性季铵盐催化的高度对映选择性迈克尔反应。通过（S）-鸟氨酸和手性2-环己烯酮的不对称合成进行说明。

  摘要：

  [分子式：见正文]手性季铵盐1a和1b的使用使对映选择性Michael反应成为可能，该反应已应用于（S）-鸟氨酸（2）和手性2-环己烯酮6的不对称合成。

  DOI：

  10.1021/ol0056527

文献信息

• ANTIINFECTIVE LIPOPEPTIDES
  申请人：Cubist Pharmaceuticals, Inc.

  公开号：EP1814588A2

  公开（公告）日：2007-08-08
• COMPOUNDS FOR THE TREATMENT OF CNS AND AMYLOID ASSOCIATED DISEASES
  申请人：Neurochem (International) Limited

  公开号：EP1817305A2

  公开（公告）日：2007-08-15
• [EN] COMPOUNDS FOR THE TREATMENT OF CNS AND AMYLOID ASSOCIATED DISEASES<br/>[FR] COMPOSES POUR LE TRAITEMENT DE MALADIES ASSOCIEES AU SNC ET A LA PROTEINE AMYLOIDE
  申请人：NEUROCHEM INT LTD

  公开号：WO2006059245A2

  公开（公告）日：2006-06-08

  [EN] Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing CNS and amyloid associated disease. Also described are methods, compounds, pharmaceutical compositions and kits for detecting, diagnosing, monitoring and treating or preventing CNS and amyloid associated disease.
  [FR] L'invention concerne des procédés, des composés, des compositions pharmaceutiques et des kits permettant de traiter ou de prévenir des maladies associées au SNC et à la protéine amyloïde. L'invention concerne également des procédés, des composés, des compositions pharmaceutiques et des kits permettant de détecter, diagnostiquer, surveiller et traiter ou prévenir des maladies associées au SNC et à la protéine amyloïde.
• [EN] ANTIINFECTIVE LIPOPEPTIDES<br/>[FR] LIPOPEPTIDES ANTI-INFECTIEUX
  申请人：CUBIST PHARM INC

  公开号：WO2006110185A2

  公开（公告）日：2006-10-19

  [EN] The present invention relates to novel depsipeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel depsipeptide compounds and intermediates used in producing these compounds.
  [FR] L'invention concerne de nouveaux composés à base de depsipeptides. Elle concerne des compositions pharmaceutiques contenant ces composés et des méthodes d'utilisation de ces composés en tant que composés antibactériens. Elle concerne également des méthodes servant à préparer ces nouveaux composés à base de depsipeptides et des intermédiaires mis en application pour préparer ces composés.
• Development of a Phase-Transfer-Catalyzed, [2,3]-Wittig Rearrangement
  作者：Scott E. Denmark、Lindsey R. Cullen

  DOI：10.1021/acs.joc.5b01759

  日期：2015.12.4

  An investigation into the use of phase-transfer catalysis for the [2,3]-sigmatropic rearrangement of allyloxy carbonyl compounds is described. Initial studies focused on identifying viable substrate classes that would undergo selective [2,3]-rearrangement under phase-transfer catalysis. Under certain conditions, the [2,3]-sigmatropic rearrangement of allyloxy carbonyl compounds takes place in the presence of a phase-transfer agent, providing a rare example of a phase-transfer-catalyzed unimolecular reaction. In the course of this investigation, it was found that catalysis is dependent on several variables including base concentration, catalyst structure, and substrate lipophilicity. Preliminary testing of chiral, nonracemic phase-transfer catalysts has shown promising levels of enantioselectivity for future development.